Answer
Pedmarqsi is licensed to reduce the risk of cisplatin-related hearing damage in eligible children and young people with localised, non-metastatic solid tumours.
Sources for this answer
- Pedmarqsi 80 mg/mL solution for infusionemc · SmPC Current selected SmPC · Version 3